CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
Lisbon, Portugal, 16-19 June 2018
Patient-reported outcomes from a pivotal Phase 2 study (NCT02066415) and the STRIVE study (NCT02456740) show beneficial effects of erenumab on headache impact, disability, absenteeism and quality of life scores.1,2 In the Phase 2 study which previously demonstrated efficacy and safety of erenumab (70 mg and 140 mg monthly) at 12 weeks in patients with chronic …
Read more »Pooled data from patients treated with galcanezumab (GMB) 120 or 240 mg in the EVOLVE-1 and 2 and REGAIN trials show significant improvements (p<0.001) in monthly migraine headache days (MHD) versus placebo, irrespective of whether patients had failed > 2 previous preventive therapies.1 Overall change in MMD: least square mean change from baseline (standard error) …
Read more »Latest results from the open-label, long-term COMPEL study have shown that onabotulinumtoxinA 155 U every 12 weeks improved anxiety and depression at week 108 in patients with chronic migraine, irrespective of whether treatment resulted in a > 50% reduction in headache day frequency.1 Amongst patients with depression and anxiety at baseline, 83.7% of headache frequency …
Read more »Nearly half of patients with episodic or chronic migraine find candesartan prophylaxis effective, even after up to nine previous preventive therapy failures. An audit of clinical records of patients treated at King’s Headache Clinic, London, from February 2015-March 2018 showed that 47% of 100 patients prescribed candesartan for at least two months reported a positive …
Read more »French migraine patients who have at least eight days of headaches per month lose an estimated 33 working days per year at an annual cost of €3.8 billion per year to French society, according to data from an online survey.1 Of the 7,720 participants, 3.8% had at least eight headaches per month (average age 41.1 …
Read more »A sub group analysis of the Phase III STRIVE study has shown that erenumab 70 mg and 140 mg monthly for six months reduce mean monthly migraine days (MMD) compared to placebo in patients with episodic migraine, with or without aura. Effects of erenumab on MMD: least squares mean (SE) changes from baseline Placebo Erenumab …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
